



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/593,382

03/14/2007

Kenneth Powell

NV2-020US

8889

959 7590 08/17/2009

LAHIVE & COCKFIELD, LLP
FLOOR 30, SUITE 3000
ONE POST OFFICE SQUARE
BOSTON, MA 02109

EXAMINER

PIHONAK, SARAH

ART UNIT

PAPER NUMBER

1617

MAIL DATE

DELIVERY MODE

08/17/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address : COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10593382	3/14/2007	POWELL ET AL.	NV2-020US

LAHIVE & COCKFIELD, LLP
FLOOR 30, SUITE 3000
ONE POST OFFICE SQUARE
BOSTON, MA 02109

EXAMINER

SARAH PIHONAK

ART UNIT	PAPER
1617	20090812

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on 6/18/2009 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s):

In the office action dated 4/28/2009, an election of species requirement was made for (a) an inhibitor of the RSV fusion protein and (b) a benzodiazepine derivative capable of inhibiting RSV replication. In the response filed on 6/18/2009, the Applicants elected an inhibitor of the RSV fusion protein as a compound of formula (I), with R1, R2, and R3=H. However, the instant claims do not include H as a selection for these functional groups. Additionally, the Applicants have elected the functional group R7 of formula (I) as being butyl alcohol. However, alcohols are not included in the instant claim 23 as a possible selection for this substituent.

Regarding the benzodiazepine derivative (b), the Applicants elected a compound of formula (V) with R1=aryl, A1=aryl, and A2=aryl. However, in the species requirement, the Applicants were requested to elect a single compound. The term "aryl" denotes a genus and encompasses more than one compound.

Applicant is reminded that a species election is directed to a single compound each of (a) an inhibitor of the RSV fusion protein and (b) a benzodiazepine derivative capable of inhibiting RSV replication. Applicants are also reminded to elect species that are within the scope of the instant claims.

Since the above-mentioned reply appears to be bona-fide, applicant is given ONE (1) MONTH of THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

/SREENI PADMANABHAN/
Supervisory Patent Examiner, Art Unit 1617

/S. P./
Examiner, Art Unit 1617